STRO (Sutro Biopharma) Debt-to-Asset : 0.06 (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma Debt-to-Asset?

Sutro Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $7.2 Mil. Sutro Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $17.7 Mil. Sutro Biopharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $451.8 Mil. Sutro Biopharma's debt to asset for the quarter that ended in Sep. 2024 was 0.06.

Sutro Biopharma Debt-to-Asset Historical Data

The historical data trend for Sutro Biopharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma Debt-to-Asset Chart

Sutro Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.06

0.17

0.12

0.07

Sutro Biopharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.09	0.07	0.07	0.05	0.06

Competitive Comparison of Sutro Biopharma's Debt-to-Asset

For the Biotechnology subindustry, Sutro Biopharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sutro Biopharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's Debt-to-Asset falls into.

Sutro Biopharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sutro Biopharma's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(10.481	+	23.154)	/	470.736
	=	0.07

Sutro Biopharma's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7.203	+	17.661)	/	451.832
	=	0.06

Sutro Biopharma (NAS:STRO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Sutro Biopharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sutro Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (NAS:STRO) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

S09:Germany

Address

111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.sutrobio.com

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Executives

Nicki Vasquez	officer: Chief Port. Strat & Alnce Ofcr	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Hans-peter Gerber	officer: Chief Scientific Officer	C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Brunilda Shtylla	officer: Chief Business Officer	C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Venkatesh Srinivasan	officer: Chief Tech Op Officer	C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Anne Elizabeth Borgman	officer: Chief Medical Officer	9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
William J Newell	director, officer: CEO & President	887 GREAT NORTHERN WAY, VANCOUVER A1 V5T 4T5
Heidi Hunter	director	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Jane Chung	officer: Chief Commercial Officer	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Trevor Hallam	officer: Chief Science Officer	PALATIN TECHNOLOGIES, INC., 4C CEDAR BROOK DRIVE, CRANBURY NJ 08512
Jon Marc Wigginton	director	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
John Gordon Freund	director, 10 percent owner	125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Arturo Md Molina	officer: Chief Medical Officer	10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Linda A Fitzpatrick	officer: Chief People & Comm. Officer	NUVELO, INC., 675 ALMANOR AVENUE, SUNNYVALE CA 94085
James P Panek	director	C/O VAXGEN INC, 1000 MARINA BLVD. #200, BRISBANE CA 94005
Matsui Connie	director	3030 CALLAN RD, SAN DIEGO CA 92121